Hara C et al., 2006-07: Japanese 2006 paper describing hospital in-house preparation of methylene blue injection for methemoglobinemia because the antidote was not commercially available in Japan, with quality tested against the United States Pharmacopoeia.
Since some antagonists or antidotes in cases of acute poisoning are not commercially available in Japan, in many hospitals they are prepared on their premises for clinical use.
257-63
Hara C et al., 2006-07: Japanese 2006 paper describing hospital in-house preparation of methylene blue injection for methemoglobinemia because the antidote was not commercially available in Japan, with quality tested against the United States Pharmacopoeia. C3 Japan (Chudoku Kenkyu – Japanese Journal of Toxicology, 19(3):257-63). Study type: hospital pharmacy practice report with quality-control testing, not a clinical trial. Preparation from reagent-grade chemical; contents checked against USP specifications. Funder/conflicts not stated. This record is direct evidence that methylene blue injection was not a commercial product in Japan at that date and was compounded in hospitals. Study type: other.
